medigraphic.com
SPANISH

Acta Médica del Centro

ISSN 1995-9494 (Electronic)
Revista del Hospital Clínico Quirúrgico "Arnaldo Milián Castro"
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2013, Number 3

<< Back Next >>

Acta Med Cent 2013; 7 (3)

Acute phase reactants in hemodialysis patients

Ortega GA, Moré CCX, Pérez AL, Rodríguez VR, Isidoria LO, López RJ
Full text How to cite this article

Language: Spanish
References: 20
Page:
PDF size: 119.80 Kb.


Key words:

chronic renal insufficiency, acute-phase proteins, renal dialysis.

ABSTRACT

cross-sectional descriptive study was conducted according to a quanti-qualitative strategy in the Nephrology Department of the Arnaldo Milian Castro Provincial University Hospital in Santa Clara from February 2011 to February 2012 in order to describe the levels of some acute phase reactants in chronic renal patients that undergo hemodialysis in this institution. All these patients (147) were studied. The ages between 45-64 years predominated, as well as males and white skin patients. The main causes of chronic kidney disease were diabetic and hypertensive renal disease, with less than one year of treatment. Comorbidities such as hypertension and hepatitis C were significant. Arteriovenous fistula was found to be the most commonly used type of vascular access. And among the acute phase reactants studied, C-reactive protein, α1-antitrypsin and fibrinogen were noteworthy by the significant increase of its levels. The levels of the complement (C3 and C4) and ceruloplasmin were not significant. In general, pathological values were not correlated with age, vascular access type or the presence of hepatitis C; and they were associated significantly to periods of less than three years on hemodialysis. It is recommended considering C-reactive protein as the most appropriate acute phase reactant in clinical practice for solitary kidney patients undergoing dialysis, and the systematizing the use of C-reactive protein, α1-antitrypsin and fibrinogen in their evaluation.


REFERENCES

  1. Fernández Andrade C. Marcadores y predictores renales y factores de riesgo renal y cardiovascular. Nefrología. 2002;22(Supl 1):2-29.

  2. Liu J, Huang Z, Gilbertson DT, Foley RN, Collins AJ. An improved comorbidity index for outcome analyses among dialysis patients. Kidney Int. 2010;77:141-51.

  3. Vasan RS. Biomarkers of cardiovascular disease. Molecular basis and practical considerations. Circulation. 2006;113:2335-62.

  4. Pérez García R, Rodríguez Benítez P, Jofre R, López Gómez JM, Carretero D, Amann R, et al. Marcadores de inflamación en los pacientes en hemodiálisis: su valor pronóstico. [Internet]. España: Elsevier; 2003 [citado 24 May 2012]. Disponible en: http://www.uninet.edu/cin2003/conf/perez/perez.html

  5. Pérez-Oliva Díaz JF, Magrans Buch C, Almaguer López M, Zambrano Cárdenas AE, Delgado G, Pérez Campo R. Guías de buenas prácticas en hemodiálisis [Internet]. Cuba: INNEF; 2003 [citado 24 May 2012]. Disponible en: http://www.sld.cu/galerias/pdf/sitios/nefrologia/guia_de_buenas_practica_clinicas_en_hemodialisis.pdf

  6. Danesh J, Collins R, Appleby P, Peto R. Association of Fibrinogen, C-reactive Protein, Albumin, or Leukocyte Count With Coronary Heart Disease. Meta-analyses of Prospective Studies. JAMA. 1998;279(18):1477-82.

  7. Rachelefsky G, Hogarth DK. Issues in the diagnosis of alpha 1-antitrypsin deficiency. J Allergy Clin Immunol. 2008 Apr;121(4):833-8. doi: 10.1016/j.jaci.2007.12.1183.

  8. Restrepo CA, Chacón JA, Villota Duván M. Safety related to the implantation of jugular catheters for hemodyalisis and usefulness of PA chest Xrays post procedure. Acta Med Colomb [Internet]. 2008 Jun [citado 14 Jun 2012];33(2):[aprox. 10 p.]. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S012024482008000200005&lng=en

  9. Miller JE, Kovesdy CP, Nissenson AR, Mehrotra R, Streja E, Wyck DV, et al. Association of Hemodialysis Treatment Time and Dose With Mortality and the Role of Race and Sex. Am J Kidney Dis. 2010 Jan;55(1):100-12.

  10. Feroze U, Noori N, Kovesdy CP, Molnar MZ, Martin DJ, Reina-Patton A, et al. Quality-of-Life and Mortality in Hemodialysis Patients: Roles of Race and Nutritional Status. Clin J Am Soc Nephrol. 2011 May;6(5):1100-11. doi: 10.2215/CJN.07690910.

  11. Contreras F, Esguerra G, Espinosa JC, Gutiérrez C, Fajardo L. Calidad de vida y adhesión al tratamiento en pacientes con insuficiencia renal crónica en tratamiento de hemodiálisis. Univ Psychol [Internet]. 2006 [citado 14 Jun 2012];5(3):[aprox. 7 p.]. Disponible en: http://pepsic.bvsalud.org/scielo.php?script=sci_arttext&pid=S165792672006000300005&lng=pt&nrm=iso

  12. Sanjuán F, Foraster A, Fabado S, de Francisco AL, Santamaría CJ. Aguilera J. Estudio epidemiológico de pacientes ancianos con insuficiencia renal crónica en hemodiálisis. Nefrología [Internet]. 2008 Sep [citado 14 jun 2012];28(1):[aprox.9 p.]. Disponible en: http://www.revistanefrologia.com/modules.php?name=articulos&idarticulo=533

  13. De Francisco ALM, San Juan F, Foraster A, Fabado S, Carretero D, Santamaría C, et al. Estudio epidemiológico de pacientes ancianos con insuficiencia renal crónica en hemodiálisis. Nefrología. 2008;28(1):48-55.

  14. Antón-Pérez G, Pérez-Borges P, Alonso-Almán F, Vega-Díaz N. Accesos vasculares en hemodiálisis: un reto por conseguir. Nefrología [Internet]. 2012 [citado 19 May 2012]; 32(1):[aprox. 9 p.]. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S021169952012000100016&lng=es

  15. Cabezas Niubó EP, Rodríguez Beirís RP, Falagán Andina C, Zamora Cabezas L, Fernández Duharte J. B and C hepatitis in patients with hemodialysis. Medisan [Internet]. 2010 Mar [citado 1 Ago 2012];14(2):[aprox. 5 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S10293019201000200002&lng=es

  16. Hernández Garcés HR, Hevia González LE, Silverio García CE, Espinoza Álvarez RF, Sonería Pérez M. Afecciones digestivas. En: Álvarez Sintes R, Hernández Cabrera G, Báster Moro JC, García Núñez RD, Louro Bernal I, Céspedes Lantigua LA, et al. Temas de Medicina General Integral. La Habana: Ciencias Médicas; 2008. p. 220-335.

  17. Zoccali C. Biomarkers in chronic kidney disease: utility and issues towards better understanding. Curr Opin Nephrol Hypertens. 2005 Nov;14(6):532-7.

  18. Fernández Travieso JC. El fibrinógeno como factor de riesgo de enfermedad aterotrombótica. Rev CENIC Ciencias Biológicas [Internet]. 2009 [citado 26 May 2012];40(1):[aprox. 9 p.]. Disponible en: http://revista.cnic.edu.cu/revistaCB/files/CB-2009-1-003-012.pdf

  19. Asakawa H, Tokunaga K, Kawakami F. Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. J Diabetes Complications. 2000 May-Jun;14(3):121-6.

  20. Jara A, Mezzano S. Daño vascular en la enfermedad renal crónica. Rev Méd Chile. 2008;136:1476-84.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Acta Med Cent. 2013;7